Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL -2.90% 3-Year EBITDA Growth Rate is 31.10% as of Dec. 2025, which is 41% above its 10-year median of 22.05. The stock has 4 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Control Bionics ranks better than 77.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 31.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Control Bionics was 31.10% per year. The lowest was 13.00% per year. And the median was 22.05% per year.
Control Bionics (ASX:CBL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Control Bionics 3-Year EBITDA Growth Rate Related Terms
ASX:CBL vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Control Bionics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Control Bionics's 3-Year EBITDA Growth Rate falls into.
Control Bionics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 31.10% mean?
Control Bionics (ASX:CBL) has a 3-Year EBITDA Growth Rate of 31.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Control Bionics and its competitors. This is 41% above median its historical median of 22.05. Over the past decade, Control Bionics' 3-Year EBITDA Growth Rate has ranged from 13.00 to 31.10. According to the industry distribution chart, Control Bionics ranks #153 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 22.1%.
Is Control Bionics' 3-Year EBITDA Growth Rate too high?
Control Bionics' current 3-Year EBITDA Growth Rate of 31.10% is 41% above median its 10-year median of 22.05. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 31.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Control Bionics' value of 31.10% is 279.3% above this industry median. Based on the distribution chart, Control Bionics ranks #153 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Control Bionics' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #153 out of 692 companies for 3-Year EBITDA Growth Rate. This places Control Bionics in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Control Bionics' value of 31.10% is 279.3% above this benchmark. Historically, Control Bionics' own 3-Year EBITDA Growth Rate has ranged from 13.00 to 31.10 over the past decade. While the company's 10-year median is 22.05 vs. the industry median of 8.20, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current 3-Year EBITDA Growth Rate of 31.10% is 279.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current 3-Year EBITDA Growth Rate is 31.10%, which is 41% above median its own 10-year median of 22.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 123.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 31.10%, which is 41% above median its 10-year median of 22.05 and 279.3% above the Medical Devices & Instruments industry median of 8.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current 3-Year EBITDA Growth Rate is 31.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
